Stock ACAD ACADIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
16.71 USD +2.45% Intraday chart for ACADIA Pharmaceuticals Inc. -0.65% -46.63%
23/04 Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada MT
22/04 Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada MT

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Number of employees: 598

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Medicines
100.0 %
517 100.0 % 726 100.0 % +40.45%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
517 100.0 % 726 100.0 % +40.45%

Managers

Managers TitleAgeSince
Stephen Davis CEO
 Chief Executive Officer 63 15/14/15
Mark Schneyer DFI
 Director of Finance/CFO 50 28/20/28
Benir Ruano CTO
 Chief Tech/Sci/R&D Officer - 01/22/01
Sanjeev Pathak CTO
 Chief Tech/Sci/R&D Officer - 01/21/01
Brendan Teehan COO
 Chief Operating Officer 56 01/18/01
Ponni Subbiah CTO
 Chief Tech/Sci/R&D Officer - 01/19/01
Albert Kildani
- -
Kimberly Manhard PRN
 Corporate Officer/Principal 64 30/01
Kevin Oliver PRN
 Corporate Officer/Principal - 10/23/10
Holly Valdiviez SAM
 Sales & Marketing - 01/22/01

Members of the board

Members of the board TitleAgeSince
Julian Baker BRD
 Director/Board Member 57 11/15/11
Edmund Harrigan BRD
 Director/Board Member 71 25/15/25
Stephen Davis CEO
 Chief Executive Officer 63 15/14/15
Don Soland BRD
 Director/Board Member 65 20/15/20
Laura Brege BRD
 Director/Board Member 66 01/08/01
Stephen Biggar CHM
 Chairman 53 22/13/22
James Daly BRD
 Director/Board Member 63 11/16/11
Elizabeth Garofalo BRD
 Director/Board Member 66 29/20/29
Adora Ndu BRD
 Director/Board Member 43 10/22/10

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 164,771,521 163,859,371 ( 99.45 %) 0 99.45 %

Shareholders

NameEquities%Valuation
Baker Bros. Advisors LP
26.01 %
42,864,612 26.01 % 793 M $
Vanguard Fiduciary Trust Co.
8.130 %
13,396,009 8.130 % 248 M $
RTW Investments LP
6.830 %
11,253,551 6.830 % 208 M $
BlackRock Advisors LLC
6.316 %
10,406,712 6.316 % 192 M $
STATE STREET CORPORATION
3.924 %
6,465,026 3.924 % 120 M $
EcoR1 Capital, LLC
3.636 %
5,991,479 3.636 % 111 M $
Fidelity Management & Research Co. LLC
3.196 %
5,265,358 3.196 % 97 M $
T. Rowe Price International Ltd.
3.143 %
5,178,509 3.143 % 96 M $
D.E. Shaw & Co., Inc.
2.279 %
3,754,598 2.279 % 69 M $
Weatherbie Capital LLC
1.928 %
3,176,775 1.928 % 59 M $

Company contact information

ACADIA Pharmaceuticals, Inc.

12830 El Camino Real Suite 400

92130-3331, San Diego

+858 558 2871

http://www.acadia.com
address ACADIA Pharmaceuticals Inc.(ACAD)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for ACADIA Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.71 USD
Average target price
29.09 USD
Spread / Average Target
+74.11%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ACADIA PHARMACEUTICALS INC. Stock ACADIA Pharmaceuticals Inc.
-46.63% 2.76B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ACAD Stock
  4. Company ACADIA Pharmaceuticals Inc.